Business Market R...
Follow
Find
3.2K views | +5 today
 
Scooped by rnrmarketresearch
onto Business Market Research Reports
Scoop.it!

2012 Sedation and Gastric Motility Disorder Pipeline Review, H2

2012 Sedation and Gastric Motility Disorder Pipeline Review, H2 | Business Market Research Reports | Scoop.it

RnR Market Research, ‘Sedation – Pipeline Review, H2 2012′, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Sedation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Sedation. Sedation – Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by RnR Market Research team.

 

Get your report copy of Sedation – Pipeline Review, H2 2012 @ http://www.rnrmarketresearch.com/sedation-pipeline-review-h2-2012-market-report.html

 

RnR Market Research, ‘Gastric Motility Disorder – Pipeline Review, H2 2012′, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Gastric Motility Disorder, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gastric Motility Disorder. Gastric Motility Disorder – Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

 

Get your report copy of Gastric Motility Disorder – Pipeline Review, H2 2012 @ http://www.rnrmarketresearch.com/gastric-motility-disorder-pipeline-review-h2-2012-market-report.html

 

Scope

 

- A snapshot of the global therapeutic scenario for Sedation and Gastric Motility Disorder.
- A review of the Sedation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Sedation pipeline and Gastric Motility Disorder pipline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

 

Reasons to buy

 

- Identify and understand important and diverse types of therapeutics under development for Sedation and Gastric Motility Disorder.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Sedation and Gastric Motility Disorder  pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the

more...
No comment yet.
Your new post is loading...
Your new post is loading...
Scooped by rnrmarketresearch
Scoop.it!

Chinese Automotive Rubber Hose Industry Report, 2014-2017

Watch the video «Chinese Automotive Rubber Hose Industry Report, 2014-2017» uploaded by Kristenmayer on Dailymotion.

rnrmarketresearch's insight:

Thanks to its huge automobile market base, China’s demand for automotive rubber hose is enormous, totaling 460 million meters and equaling RMB 17.4 billion in market scale in 2013. As automobile industry develops further, the demand for automotive rubber hose will maintain a steady growth trend, with demand expected to reach 640 million meters and market size at RMB 24.1 billion.

 

According to function, automotive rubber hose can be divided into engine hose, fuel hose, air conditioner hose, brake hose, power steering hose, etc. Seen from market demand, engine hose is the most prominent in terms of scale, accounting for nearly 28% of total market demand for hose in 2013 and estimated to exceed 170 million meters in 2017. From the perspective of market value, fuel hose is the largest segment as concerns scale, topping RMB 5 billion in 2013, more than 29% of total market value of automotive rubber hose and expected to hit RMB 7 billion by 2017, higher than that of other types of hoses.

 

Competitors in the Chinese automotive rubber hose market consist mainly of two camps, namely, foreign companies and local ones, of which the former serves chiefly upscale and luxury car models, while local ones support low and medium-end car models.

View Complete Report @ http://www.chinamarketresearchreports.com/114910.html .

more...
No comment yet.
Scooped by rnrmarketresearch
Scoop.it!

Xarelto Market (Acute Coronary Syndrome) Overview to 2023

MarketOptimizer.org adds report “Xarelto (Acute Coronary Syndrome) – Forecast and Market Analysis to 2023” to its store.

 

GlobalData has released its new PharmaPoint Drug Evaluation report, “Xarelto (Acute Coronary Syndrome) Forecast and Market Analysis to 2023″. The current ACS market primarily comprised of antithrombotics, antihypertensives, and statins is flush with well-established standard-of-care therapies, many of which are generic. Therefore, the pipeline therapies that show the most promise exploit novel mechanisms of action and target orphan biochemical pathways. The ACS market will be driven by an aging population with a preponderance of lifestyle-based diseases, such as obesity, and the growing prevalence of metabolic disorders such as diabetes. The expansion of biologics into the ACS mainstream during the ten year forecast period is expected to significantly and fundamentally alter the ACS market, both medically and financially.

 

Xarelto was approved in the EU for the prevention of non-valvular atrial fibrillation (AF)-related stroke and systemic embolism, and for the treatment of deep vein thrombosis (DVT). On July 1, 2011, Xarelto was approved in the US to reduce the risk of blood clots, DVT, and pulmonary embolism (PE) following hip or knee replacement surgery, and in November of the same year, it was approved for stroke prevention in patients with non-valvular AF.

 

Complete report available @ http://www.marketoptimizer.org/xarelto-acute-coronary-syndrome-forecast-and-market-analysis-to-2023.html .

 

Scope

 

Overview of ACS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.Detailed information on Aricept including product description, safety and efficacy profiles as well as a SWOT analysis.Sales forecast for Aricept for the top seven countries from 2013 to 2023.Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.

 

Inquire before Buying @ http://www.marketoptimizer.org/contacts/inquire-before-buying?rname=10448 .

(This is a premium report priced at US$3495 for a single user PDF.)

 

Reasons to buy

 

Understand and capitalize by identifying products that are most likely to ensure a robust returnStay ahead of the competition by understanding the changing competitive landscape for ACSEffectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potentialMake more informed business decisions from insightful and in-depth analysis of Aricept performanceObtain sales forecast for Aricept from 2013-2023 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

 

Purchase a copy of this report @ http://www.marketoptimizer.org/contacts/purchase?rname=10448 .

 

About Us:

 

MarketOptimizer.org is your single source for all market research needs. Our database includes 450,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. We offer you customization options on reports by & custom reports through MarketsandMarkets.com. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

more...
No comment yet.
Scooped by rnrmarketresearch
Scoop.it!

Carbon Fiber Fabric Market 2009-2019 Research Report for Global... - RnR Market Research

Market Research Report on Global and Chinese Carbon Fiber Fabric Industry, 2009-2019 is a professional and in-depth market survey on Global and Chinese...
more...
No comment yet.
Scooped by rnrmarketresearch
Scoop.it!

Brilinta Market (Acute Coronary Syndrome) Market Forecast &... - RnR Market Research

MarketOptimizer.org adds report “Brilinta (Acute Coronary Syndrome) – Forecast and Market Analysis to 2023” to its store.
more...
No comment yet.
Scooped by rnrmarketresearch
Scoop.it!

2020 China Non-Vascular Stents Industry Research Report - RnR Market Research

China Non-Vascular Stents Market Outlook to 2020: Order report by calling marketoptimizer.org at +1 888 391 5441 OR send an email on...
more...
No comment yet.
Scooped by rnrmarketresearch
Scoop.it!

Brilinta (Acute Coronary Syndrome) – Forecast and Market Analysis to 2023

MarketOptimizer.org adds report “Brilinta (Acute Coronary Syndrome) – Forecast and Market Analysis to 2023” to its store.

 

GlobalData has released its new PharmaPoint Drug Evaluation report, “Brilinta (Acute Coronary Syndrome) Forecast and Market Analysis to 2023″. The current ACS market primarily comprised of antithrombotics, antihypertensives, and statins is flush with well-established standard-of-care therapies, many of which are generic. Therefore, the pipeline therapies that show the most promise exploit novel mechanisms of action and target orphan biochemical pathways. The ACS market will be driven by an aging population with a preponderance of lifestyle-based diseases, such as obesity, and the growing prevalence of metabolic disorders such as diabetes. The expansion of biologics into the ACS mainstream during the ten year forecast period is expected to significantly and fundamentally alter the ACS market, both medically and financially.

 

Ticagrelor was approved for use in the EU in December 2010 (AstraZeneca, press release, December 6, 2010) under the brand name Brilique. In July 2011, the FDA approved ticagrelor for use in the US under the brand name Brilinta (AstraZeneca, press release, July 20, 2011). Brilinta is indicated for use in patients during the acute phase of ACS, along with standard aspirin therapy, at a loading dose of 180mg. During the chronic treatment phase, 90mg doses are taken twice daily with maintenance doses of aspirin not to exceed 100mg.

 

Complete report available @ http://www.marketoptimizer.org/brilinta-acute-coronary-syndrome-forecast-and-market-analysis-to-2023.html .

 

Scope

 

Overview of ACS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.Detailed information on Aricept including product description, safety and efficacy profiles as well as a SWOT analysis.Sales forecast for Aricept for the top seven countries from 2013 to 2023.Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan

 

Inquire before Buying @ http://www.marketoptimizer.org/contacts/inquire-before-buying?rname=10445 .

(This is a premium report priced at US$3495 for a single user PDF.)

 

Reasons to buy

 

Understand and capitalize by identifying products that are most likely to ensure a robust returnStay ahead of the competition by understanding the changing competitive landscape for ACSEffectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potentialMake more informed business decisions from insightful and in-depth analysis of Aricept performanceObtain sales forecast for Aricept from 2013-2023 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

 

Purchase a copy of this report @ http://www.marketoptimizer.org/contacts/purchase?rname=10445 .

 

About Us:

 

MarketOptimizer.org is your single source for all market research needs. Our database includes 450,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. We offer you customization options on reports by & custom reports through MarketsandMarkets.com. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

 

 

more...
No comment yet.
Scooped by rnrmarketresearch
Scoop.it!

High Plains Power, Inc.– Power Plants and SWOT Analysis, 2013 - RnR Market Research

High Plains Power, Inc. – Power Plants and SWOT Analysis, 2013 Update: Order report by calling marketoptimizer.org at +1 888 391 5441 OR send an email on...
more...
No comment yet.
Scooped by rnrmarketresearch
Scoop.it!

Repsol S.A. – Power Plants and SWOT Analysis, 2013 - RnR Market Research

Repsol S.A. – Power Plants and SWOT Analysis, 2013 Update: Order report by calling marketoptimizer.org at +1 888 391 5441 OR send an email on...
more...
No comment yet.
Scooped by rnrmarketresearch
Scoop.it!

Wabash Valley Power Association – Power Plants and SWOT Analysis, 2013 - RnR Market Research

Wabash Valley Power Association – Power Plants and SWOT Analysis, 2013 Update: Order report by calling marketoptimizer.org at +1 888 391 5441 OR send an...
more...
No comment yet.
Scooped by rnrmarketresearch
Scoop.it!

Global and China Stem Cell Industry Report, 2014-2017 by Research In China at China Market Research Reports

Global and China Stem Cell Industry Report, 2014-2017 by Research In China at China Market Research Reports | Business Market Research Reports | Scoop.it
Global and China Stem Cell Industry Report, 2014-2017 published in Sep 2014 Available for US $ 2250 at ChinaMarketResearchReports.com - Buy Now or Inquire about this report online.
rnrmarketresearch's insight:

Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Stem cell therapy can be applied to treatment of cardiovascular diseases, leukemia (a kind of hematological system disease), nervous system diseases, damage or lesion of liver, kidney and other parenchymal organs, etc.

 

Currently, cord blood bank is the fastest-growing and relatively mature market amid stem cell upstream sectors and even the whole industry chain. In 2005, there were 23 cord blood banks worldwide and in 2013 the figure exceeded 480. Global cord blood stem cell (CBSC) storage companies can be roughly divided into two categories: the ones running in a globalized business model, such as Cryo-Cell International and Esperite (formerly known as Cryo-Save Group), and the others giving priority to regional operation e.g. Zhongyuan Union Stem Cell Bioengineering (VCANBIO), Golden Meditech and LifeCell International. However, the companies mainly engaged in cord blood bank business are currently small in scale, only a few with more than 500,000 clients.

 

View Complete Report @ http://www.chinamarketresearchreports.com/114908.html .

more...
No comment yet.
Scooped by rnrmarketresearch
Scoop.it!

Giant Cell Arteritis Therapeutics Clinical Trials Industry... - RnR Market Research

Giant Cell Arteritis Global Clinical Trials Review, H2, 2014: Order report by calling marketoptimizer.org at +1 888 391 5441 OR send an email on...
more...
No comment yet.
Scooped by rnrmarketresearch
Scoop.it!

Heart Valve Disease Therapeutics Clinical Trials Market Review,... - RnR Market Research

Heart Valve Disease Global Clinical Trials Review, H2, 2014: Order report by calling marketoptimizer.org at +1 888 391 5441 OR send an email on...
more...
No comment yet.
Scooped by rnrmarketresearch
Scoop.it!

Hematoma Therapeutics Clinical Trials Industry Analysis H2 2014

MarketOptimizer.org adds report “Hematoma Global Clinical Trials Review, H2, 2014” to its store.

 

“Hematoma Global Clinical Trials Review, H2, 2014″ provides data on the Hematoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hematoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hematoma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

 

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

 

Complete report available @ http://www.marketoptimizer.org/hematoma-global-clinical-trials-review-h2-2014.html .

 

Scope

 

Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nationsClinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor typeListings of discontinued trials (suspended, withdrawn and terminated)

 

Inquire before Buying @ http://www.marketoptimizer.org/contacts/inquire-before-buying?rname=10419 .

(This is a premium report priced at US$2500 for a single user PDF.)

 

Reasons To Buy

 

Understand the dynamics of a particular indication in a condensed mannerAbridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many moreObtain discontinued trial listing for trials across the globeEspy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

 

Purchase a copy of this report @ http://www.marketoptimizer.org/contacts/purchase?rname=10419 .

 

About Us:

 

MarketOptimizer.org is your single source for all market research needs. Our database includes 450,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. We offer you customization options on reports by & custom reports through MarketsandMarkets.com. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

 

 

more...
No comment yet.
Scooped by rnrmarketresearch
Scoop.it!

Angiomax Market (Acute Coronary Syndrome) Overview to 2023

MarketOptimizer.org adds report “Angiomax (Acute Coronary Syndrome) – Forecast and Market Analysis to 2023” to its store.

 

GlobalData has released its new PharmaPoint Drug Evaluation report, “Angiomax (Acute Coronary Syndrome) Forecast and Market Analysis to 2023″. The current ACS market primarily comprised of antithrombotics, antihypertensives, and statins is flush with well-established standard-of-care therapies, many of which are generic. Therefore, the pipeline therapies that show the most promise exploit novel mechanisms of action and target orphan biochemical pathways. The ACS market will be driven by an aging population with a preponderance of lifestyle-based diseases, such as obesity, and the growing prevalence of metabolic disorders such as diabetes. The expansion of biologics into the ACS mainstream during the ten year forecast period is expected to significantly and fundamentally alter the ACS market, both medically and financially.

 

The Medicines Company launched its novel anticoagulant, Angiomax (bivalirudin), in the US in January 2001 following approval by the US FDA in December of the previous year. Bivalirudin was subsequently approved for use in the EU in 2004 under the trade name Angiox. Bivalirudin, a small molecule peptide, is a direct thrombin inhibitor. It is administered intravenously during the acute phase of ACS and is indicated for use in patients undergoing PCI.

 

Complete report available @ http://www.marketoptimizer.org/angiomax-acute-coronary-syndrome-forecast-and-market-analysis-to-2023.html .

 

Scope

 

Overview of ACS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.Detailed information on Aricept including product description, safety and efficacy profiles as well as a SWOT analysis.Sales forecast for Aricept for the top seven countries from 2013 to 2023.Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.

 

Inquire before Buying @ http://www.marketoptimizer.org/contacts/inquire-before-buying?rname=10449 .

(This is a premium report priced at US$3495 for a single user PDF.)

 

Reasons to buy

 

Understand and capitalize by identifying products that are most likely to ensure a robust returnStay ahead of the competition by understanding the changing competitive landscape for ACSEffectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potentialMake more informed business decisions from insightful and in-depth analysis of Aricept performanceObtain sales forecast for Aricept from 2013-2023 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

 

Purchase a copy of this report @ http://www.marketoptimizer.org/contacts/purchase?rname=10449 .

 

About Us:

 

MarketOptimizer.org is your single source for all market research needs. Our database includes 450,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. We offer you customization options on reports by & custom reports through MarketsandMarkets.com. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

more...
No comment yet.
Scooped by rnrmarketresearch
Scoop.it!

Crestor Market (Acute Coronary Syndrome) 2023 | Health

MarketOptimizer.org adds report “Crestor (Acute Coronary Syndrome) – Forecast and Market Analysis to 2023” to its store.

 

GlobalData has released its new PharmaPoint Drug Evaluation report, “Crestor (Acute Coronary Syndrome) Forecast and Market Analysis to 2023″. The current ACS market primarily comprised of antithrombotics, antihypertensives, and statins is flush with well-established standard-of-care therapies, many of which are generic. Therefore, the pipeline therapies that show the most promise exploit novel mechanisms of action and target orphan biochemical pathways. The ACS market will be driven by an aging population with a preponderance of lifestyle-based diseases, such as obesity, and the growing prevalence of metabolic disorders such as diabetes. The expansion of biologics into the ACS mainstream during the ten year forecast period is expected to significantly and fundamentally alter the ACS market, both medically and financially.

 

Crestor remains the only branded statin in the 7MM covered in this forecast. It is the most potent of all of the HMG-CoA reductase inhibitors. Crestor faces steep competition from the generic statins, especially atorvastatin, which can boast a low cost and a preponderance of clinical trial data in support of its efficacy and safety. Nevertheless, when Crestor’s patent expires in the US in 2016 and in the EU and Japan in 2017, the use of rosuvastatin is likely to increase, but the gain in sales is likely to be allocated to the new generic options.

 

Complete report available @ http://www.marketoptimizer.org/crestor-acute-coronary-syndrome-forecast-and-market-analysis-to-2023.html .

 

Scope

 

Overview of ACS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.Detailed information on Aricept including product description, safety and efficacy profiles as well as a SWOT analysis.Sales forecast for Aricept for the top seven countries from 2013 to 2023.Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.

 

Inquire before Buying @ http://www.marketoptimizer.org/contacts/inquire-before-buying?rname=10447 .

(This is a premium report priced at US$3495 for a single user PDF.)

 

Reasons to buy

 

Understand and capitalize by identifying products that are most likely to ensure a robust returnStay ahead of the competition by understanding the changing competitive landscape for ACSEffectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potentialMake more informed business decisions from insightful and in-depth analysis of Aricept performanceObtain sales forecast for Aricept from 2013-2023 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

 

Purchase a copy of this report @ http://www.marketoptimizer.org/contacts/purchase?rname=10447 .

 

About Us:

 

MarketOptimizer.org is your single source for all market research needs. Our database includes 450,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. We offer you customization options on reports by & custom reports through MarketsandMarkets.com. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

more...
No comment yet.
Scooped by rnrmarketresearch
Scoop.it!

Cement Market 2009-2019 Research Report for Global and China - RnR Market Research

Market Research Report on Global and Chinese Cement Industry, 2009-2019 is a professional and in-depth market survey on Global and Chinese Cement industry.
more...
No comment yet.
Scooped by rnrmarketresearch
Scoop.it!

2023 Effient Market (Acute Coronary Syndrome) Research - RnR Market Research

MarketOptimizer.org adds report “Effient (Acute Coronary Syndrome) – Forecast and Market Analysis to 2023” to its store.
more...
No comment yet.
Scooped by rnrmarketresearch
Scoop.it!

Effient Market (Acute Coronary Syndrome) Insights to 2023

MarketOptimizer.org adds report “Effient (Acute Coronary Syndrome) – Forecast and Market Analysis to 2023” to its store.

 

GlobalData has released its new PharmaPoint Drug Evaluation report, “Effient (Acute Coronary Syndrome) Forecast and Market Analysis to 2023″. The current ACS market primarily comprised of antithrombotics, antihypertensives, and statins is flush with well-established standard-of-care therapies, many of which are generic. Therefore, the pipeline therapies that show the most promise exploit novel mechanisms of action and target orphan biochemical pathways. The ACS market will be driven by an aging population with a preponderance of lifestyle-based diseases, such as obesity, and the growing prevalence of metabolic disorders such as diabetes. The expansion of biologics into the ACS mainstream during the ten year forecast period is expected to significantly and fundamentally alter the ACS market, both medically and financially.

 

Effient is an antiplatelet blood thinner that inhibits the P2Y12 receptor. Inhibition of P2Y12 blocks key signaling events in platelets that lead to coagulation. Effient is supplied as 10mg tablets and is administered as a 60mg loading dose during the acute phase of ACS, and as a once-daily 10mg maintenance dose during the chronic phase of ACS for the first year following an ACS event. Effient is indicated to reduce the occurrence of CV events in ACS patients managed with PCI.

 

Complete report available @ http://www.marketoptimizer.org/effient-acute-coronary-syndrome-forecast-and-market-analysis-to-2023.html .

 

Scope

 

Overview of ACS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.Detailed information on Aricept including product description, safety and efficacy profiles as well as a SWOT analysis.Sales forecast for Aricept for the top seven countries from 2013 to 2023.Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.

 

Inquire before Buying @ http://www.marketoptimizer.org/contacts/inquire-before-buying?rname=10446 .

(This is a premium report priced at US$3495 for a single user PDF.)

 

Reasons to buy

 

Understand and capitalize by identifying products that are most likely to ensure a robust returnStay ahead of the competition by understanding the changing competitive landscape for ACSEffectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potentialMake more informed business decisions from insightful and in-depth analysis of Aricept performanceObtain sales forecast for Aricept from 2013-2023 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

 

Purchase a copy of this report @ http://www.marketoptimizer.org/contacts/purchase?rname=10446 .

 

About Us:

 

MarketOptimizer.org is your single source for all market research needs. Our database includes 450,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. We offer you customization options on reports by & custom reports through MarketsandMarkets.com. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

more...
No comment yet.
Scooped by rnrmarketresearch
Scoop.it!

Global Asthma Market Overview to 2023

MarketOptimizer.org adds report “EpiCast Report: Asthma – Epidemiology Forecast to 2023” to its store.

 

Asthma is a chronic inflammatory lung disease that affects persons of all ages, but most commonly starts in childhood. It is a common long-term condition characterized by narrowing of the airways, leading to airflow limitation and airway hyper-responsiveness whenever the lungs come into contact with endogenous and exogenous irritants. Exposure to irritants instigates a series of events, such as swelling of the airways, tightening of the respiratory muscles, and increased mucus production, leading to reduced airflow into the lungs.

 

In 2013, there were 137.66 million lifetime prevalent cases of asthma in the 10MM, with 82.71 million cases in the US (43.16 million cases) and India (39.55 million cases) combined. GlobalData epidemiologists forecast that there will be approximately 161.02 million lifetime prevalent cases of asthma in the 10MM by 2023, with an overall growth of 17.0% over the next decade.

 

Complete report available @ http://www.marketoptimizer.org/epicast-report-asthma-epidemiology-forecast-to-2023.html .

 

GlobalData epidemiologists forecast the prevalent cases of asthma in the 10MM from 2013-2023 using country-specific studies published in peer-reviewed journals that provided the age- and sex-specific prevalence of asthma in the respective markets. The epidemiologists made sure that all the selected nationally-representative studies in the respective countries assessed the lifetime asthma prevalence using the same study definition, thereby ensuring that the results forecast for each country are comparable. In addition, the lifetime prevalent cases of asthma in each country were further segmented by asthma severity based on the Global Initiative for Asthma guidelines. The forecast methodology was consistent across all the 10MM to allow for a meaningful comparison among them.

 

Scope

 

The Asthma EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for asthma in the ten major markets (10MM) (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India). It includes a 10-year epidemiological forecast of the lifetime prevalent cases of asthma segmented by sex, age (in five-year increments beginning at 0 years and ending at =85 years), and asthma severity in these markets.The Asthma epidemiology report is written and developed by Masters- and PhD-level epidemiologists.The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 10MM.

 

 

Inquire before Buying @ http://www.marketoptimizer.org/contacts/inquire-before-buying?rname=10456 .

(This is a premium report priced at US$3995 for a single user PDF.)

 

Reasons to buy

 

Develop business strategies by understanding the trends shaping and driving the global Asthma market.Quantify patient populations in the global Asthma market to improve product design, pricing, and launch plans.Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for Asthma therapeutics in each of the markets covered.

 

Purchase a copy of this report @ http://www.marketoptimizer.org/contacts/purchase?rname=10456 .

 

About Us:

 

MarketOptimizer.org is your single source for all market research needs. Our database includes 450,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. We offer you customization options on reports by & custom reports through MarketsandMarkets.com. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

 

 

more...
No comment yet.
Scooped by rnrmarketresearch
Scoop.it!

Global Colored Glazing Glass Industry - product technology... - RnR Market Research

The Report “2014 Market Research Report on Global Colored Glazing Glass Industry" Provides Key Market Data On Global Colored Glazing Glass Market.
more...
No comment yet.
Scooped by rnrmarketresearch
Scoop.it!

TransAlta Corporation – Power Plants and SWOT Analysis, 2013 - RnR Market Research

TransAlta Corporation – Power Plants and SWOT Analysis, 2013 Update: Order report by calling marketoptimizer.org at +1 888 391 5441 OR send an email on...
more...
No comment yet.
Scooped by rnrmarketresearch
Scoop.it!

China PTCA Balloon Market Investment Report, 2014-201

China PTCA Balloon Market Investment Report, 2014-201 | Business Market Research Reports | Scoop.it
Check Out Details: www.studymode.com/essays/Ptca-Balloon-Market-Investment-I... PTCA balloon, as a indispensable medical device in percutaneous coronary intervention (PCI), serves not only as a delivery system for stent, but also as a device for pre-/post-stent dilatations. Therefore, the development of PTCA balloon industry is closely related to that of PCI. Despite year-on-year growth in the number of PCI cases in China, the penetration is still very low. In 2013, 309.42 per 1 million were people receiving PCI treatment in China, compared with 1800 cases in the United States, showing a vast space for development of the Chinese PCI market and a bright future for PTCA balloon industry. It is expected that China’s demand for PTCA balloon will hit 1.824 million sets by 2016.
more...
No comment yet.
Scooped by rnrmarketresearch
Scoop.it!

2014 Hematoma Therapeutics Clinical Trials Market H2 - RnR Market Research

MarketOptimizer.org adds report “Hematoma Global Clinical Trials Review, H2, 2014” to its store.
more...
No comment yet.
Scooped by rnrmarketresearch
Scoop.it!

Hot Flashes Therapeutics Clinical Trials Market Insights H2 2014 - RnR Market Research

Hot Flashes Global Clinical Trials Review, H2, 2014: Order report by calling marketoptimizer.org at +1 888 391 5441 OR send an email on...
more...
No comment yet.
Scooped by rnrmarketresearch
Scoop.it!

Heart Attack Therapeutics Clinical Trials Market Review H2 2014

“Heart Attack Global Clinical Trials Review, H2, 2014″ provides data on the Heart Attack clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Heart Attack. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Heart Attack. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
more...
No comment yet.